


Advanced Chemical Industries PLC


Condensed Interim Financial Statements
3rd quarter ended report 2024-2025
for the nine months period ended on 31 March 2025


Advanced Chemical Industries PLC


Statement of financial position
Unaudited

	Note	Figures in '000' Taka	
		As at 31 March 2025	As at 30 June 2024
Assets			
Property, plant and equipment	2	18,843,595	17,951,455
Right-of-use assets		591,824	688,959
Investments	3	3,971,452	3,632,438
Intangible assets		10,428	10,644
Biological assets		56,383	52,493
Non-current assets		23,473,682	22,335,988
Inventories	4	9,499,072	8,710,393
Trade receivables	5	4,928,035	4,036,880
Other receivables		924,175	743,954
Inter-company receivables	6	40,145,856	34,127,510
Current tax assets		1,045,552	1,001,981
Advances, deposits and prepayments	7	1,589,928	1,918,300
Cash and cash equivalents		1,167,570	1,243,417
Current assets		59,300,188	51,782,435
Total assets		82,773,870	74,118,423
Equity			
Share capital		878,612	762,056
Share premium		457,210	402,310
Merger consideration shares reserve		-	56,854
Reserves		4,869,904	4,877,506
Retained earnings		21,771,172	18,765,010
Total equity		27,976,897	24,863,737
Liabilities			
Employee benefits	8	1,796,954	1,558,453
Long term borrowings	9	1,578,388	1,692,941
Non-current portion of lease liabilities		453,530	488,415
Deferred tax liabilities		263,245	300,417
Non-current liabilities		4,092,116	4,040,226
Bank overdraft		7,864,067	6,059,933
Loans and borrowings	10	29,058,050	27,235,242
Current portion of lease liabilities		182,097	187,024
Trade payables		1,424,451	1,419,329
Inter-company payables	11	6,909,082	6,261,434
Other payables	12	5,257,185	4,043,278
Unclaimed/unpaid dividend account		9,924	8,222
Current liabilities		50,704,856	45,214,461
Total liabilities		54,796,972	49,254,687
Total equity and liabilities		82,773,870	74,118,423
Net asset value (NAV) per share (in Taka)		318.42	282.99


Managing Director


Director


Chief Financial Officer


Company Secretary

Advanced Chemical Industries PLC
Statement of profit or loss
Unaudited


Figures in '000' Taka


	Note	For the nine month ended from		For the 3rd quarter ended from	
		July 2024 to March 2025	July 2023 to March 2024	January 2025 to March 2025	January 2024 to March 2024
Revenue	13	34,427,276	25,975,066	12,025,727	8,429,824
Cost of sales	14	(21,517,457)	(15,213,350)	(7,580,866)	(4,795,000)
Gross profit		12,909,819	10,761,716	4,444,861	3,634,824
Administrative, selling and distribution expenses	15	(8,830,221)	(8,471,425)	(2,942,665)	(2,761,465)
Other income		1,336,551	954,355	43,489	35,699
Operating profit		5,416,150	3,244,646	1,545,686	909,058
Net finance costs		(905,890)	(158,513)	(249,879)	(36,434)
Profit before contribution to WPPF		4,510,260	3,086,133	1,295,807	872,624
Contribution to WPPF		(225,513)	(154,307)	(64,790)	(43,631)
Profit before tax		4,284,747	2,931,827	1,231,017	828,993
Income tax expense		(1,011,181)	(631,929)	(335,007)	(200,103)
Profit after tax		3,273,566	2,299,897	896,010	628,890


Earnings per share


Basic and diluted earnings per share (EPS) (in Taka)	37.26	26.18	10.20	7.16
--	-------	-------	-------	------

*Financials of July 2024 to March 2025 include effect of merger with Premiaflex Plastics Limited.


 Managing Director


 Director


 Chief Financial Officer


 Company Secretary

Advanced Chemical Industries PLC
Statement of profit or loss and other comprehensive income
Unaudited

	For the nine month ended from		Figures in '000' Taka	
	July 2024 to March 2025	July 2023 to March 2024	For the 3rd quarter ended from January 2025 to March 2025	January 2024 to March 2024
Profit after tax	3,273,566	2,299,897	896,010	628,890
Other comprehensive income:				
Change in fair value of FVOCI financial assets	(8,944)	(29,648)	-	(23,719)
Income tax on FVOCI financial assets	1,342	2,965	-	2,372
Other comprehensive income, net of tax	(7,603)	(26,683)	-	(21,347)
Total comprehensive income	3,265,963	2,273,214	896,010	607,543

Advanced Chemical Industries PLC
Statement of changes in equity
Unaudited

	Figures in '000' Taka							
	For the nine month ended from July 2024 to March 2025							
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total equity
Balance at 1 July 2024	762,056	402,310	56,854	1,671	291,665	4,584,170	18,765,010	24,863,737
Total comprehensive income								
Profit after tax	-	-	-	-	-	-	3,273,566	3,273,566
Other comprehensive income, net of tax	-	-	-	-	(7,603)	-	-	(7,603)
Total comprehensive income	-	-	-	-	(7,603)	-	3,273,566	3,265,963
Transaction with owners of the Company								
Issuance of merger consideration share	1,954	54,900	(56,854)	-	-	-	-	-
Stock dividend	114,602	-	-	-	-	-	(114,602)	-
Cash dividend	-	-	-	-	-	-	(152,802)	(152,802)
Total transactions with owners of the Company	116,555	54,900	(56,854)	-	-	-	(267,404)	(152,802)
Balance at 31 March 2025	878,612	457,210	-	1,671	284,063	4,584,170	21,771,172	27,976,897

	For the nine months ended from July 2023 to March 2024							
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total equity
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total equity
Balance at 1 July 2023	762,056	402,310	-	1,671	393,444	4,157,372	15,703,474	21,420,328
Total comprehensive income								
Profit after tax	-	-	-	-	-	-	2,299,897	2,299,897
Other comprehensive income, net of tax	-	-	-	-	(26,683)	-	-	(26,683)
Total comprehensive income	-	-	-	-	(26,683)	-	2,299,897	2,273,214
Transaction with owners of the Company								
Stock dividend	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	(304,823)	(304,823)
Total transactions with owners of the Company	-	-	-	-	-	-	(304,823)	(304,823)
Balance at 31 March 2024	762,056	402,310	-	1,671	366,761	4,157,372	17,698,549	23,388,720


Advanced Chemical Industries PLC
Statement of cash flows
Unaudited

	Figures in '000' Taka	
	For the nine month ended from	
	July 2024 to March 2025	July 2023 to March 2024
Cash flows from operating activities		
Cash receipts from customers and others	33,704,987	26,088,048
Cash paid to suppliers and employees	(29,415,140)	(23,424,636)
Cash generated from / (used in) operating activities	4,289,848	2,663,412
Paid to WPPF	(209,270)	(149,541)
Finance costs paid	(414,341)	(102,308)
Income tax paid	(1,090,583)	(661,735)
	(1,714,193)	(913,584)
Net cash from / (used in) operating activities*	16	1,749,828
Cash flows from investing activities		
Acquisition of property, plant and equipment	(377,470)	(416,881)
Payments for capital work-in-progress	(1,011,735)	(775,209)
Sale proceeds from property, plant and equipment	7,505	2,886
Purchase of biological assets	(6,314)	(14,894)
Dividend received	1,002,259	490,539
Investment	(347,958)	(184,434)
Net cash from / (used in) investing activities	(733,712)	(897,993)
Cash flows from financing activities		
Inter-company debts received/(paid)	(5,352,575)	(1,661,960)
Dividend paid	(151,099)	(303,629)
Payment for lease liabilities	(148,085)	(139,676)
Short-term borrowing received/(paid)	1,993,663	2,491,571
Long-term borrowing received/(paid)	(64,334)	293,969
Net cash from / (used in) financing activities	(3,722,430)	680,275
Net increase / (decrease) in cash and cash equivalents	(1,880,489)	1,532,110
Opening cash and cash equivalents	(4,816,516)	(4,667,536)
Effect of movements in exchange rates on cash held	508	2,973
Closing cash and cash equivalents	(6,696,497)	(3,132,453)
Closing balance represents		
Cash and cash equivalents	1,167,570	1,621,901
Bank overdraft	(7,864,067)	(4,754,354)
	(6,696,497)	(3,132,453)
Net operating cash flow per share (NOCFPS) (in Taka)	29.32	19.92

*See Note 16 for reconciliation of net operating cash flow.


Advanced Chemical Industries PLC
Consolidated statement of financial position
Unaudited

		Figures in '000' Taka	
	Note	As at 31 March 2025	As at 30 June 2024
Assets			
Property, plant and equipment	2 (a)	34,827,192	33,811,986
Right-of-use assets		2,947,743	3,184,834
Equity-accounted investees		2,624,399	2,920,871
Other investments		1,415,441	1,131,177
Intangible assets		1,399,163	1,415,465
Biological assets		56,383	52,493
Deferred tax assets		662,459	532,202
Non-current assets		43,932,780	43,049,028
Inventories	4 (a)	25,158,524	21,290,152
Trade receivables	5 (a)	22,645,388	17,639,830
Other receivables		1,073,809	1,021,788
Advances, deposits and prepayments	7 (a)	4,635,333	4,631,596
Current tax assets		668,029	675,485
Short term investments		204,251	196,492
Cash and cash equivalents		6,566,609	5,590,360
Current assets		60,951,942	51,045,703
Total assets		104,884,722	94,094,731
Equity			
Share capital		878,612	762,056
Share premium		1,309,016	1,254,116
Merger consideration shares reserve		-	56,854
Reserves		5,952,116	6,069,477
Accumulated loss		(2,244,172)	(1,176,671)
Equity attributable to owners of the Company		5,895,571	6,965,832
Non-controlling interests		1,373,196	1,591,894
Total equity		7,268,768	8,557,727
Liabilities			
Employee benefits	8 (a)	2,310,329	1,986,827
Long term borrowings	9 (a)	5,912,157	6,943,562
Non-current portion of lease liabilities		2,421,526	2,520,229
Non-current liabilities		10,644,011	11,450,618
Bank overdraft		10,255,077	8,697,868
Loans and borrowings	10 (a)	58,323,431	48,020,336
Current portion of lease liabilities		607,640	569,534
Trade payables		7,788,144	7,424,167
Other payables	12 (a)	9,920,080	9,364,909
Unclaimed/unpaid dividend account		77,571	9,572
Current liabilities		86,971,944	74,086,386
Total liabilities		97,615,954	85,537,004
Total equity and liabilities		104,884,722	94,094,731
Net asset value (NAV) per share (in Taka)	18	67.10	79.28


Managing Director


Director



Chief Financial Officer



Company Secretary

Advanced Chemical Industries PLC
Consolidated statement of profit or loss
Unaudited

		Figures in '000' Taka			
		For the nine month ended from		For the 3rd quarter ended from	
		July 2024 to March 2025	July 2023 to March 2024	January 2025 to March 2025	January 2024 to March 2024
	Note				
Revenue	13 (a)	101,932,506	92,962,674	35,735,085	30,519,345
Cost of sales	14 (a)	(76,574,159)	(70,748,245)	(27,039,491)	(23,082,933)
Gross profit		25,358,346	22,214,429	8,695,594	7,436,412
Administrative, selling and distribution expenses	15 (a)	(17,731,317)	(16,905,774)	(6,051,886)	(5,647,137)
Other income		321,419	390,028	113,467	277,366
Operating profit		7,948,449	5,698,684	2,757,175	2,066,641
Share of the profit of equity accounted investees		364,099	497,020	106,787	179,573
Net finance costs		(6,685,097)	(4,723,848)	(2,248,397)	(1,627,589)
Profit before contribution to WPPF		1,627,451	1,471,856	615,564	618,625
Contribution to WPPF		(358,900)	(278,084)	(105,559)	(81,344)
Profit before tax		1,268,551	1,193,772	510,005	537,281
Income tax expense		(2,051,560)	(1,668,652)	(646,981)	(520,701)
Profit/ (loss) after tax		(783,009)	(474,881)	(136,976)	16,580
Profit/ (loss) attributable to:					
Owners of the Company		(800,098)	(630,434)	(98,005)	11,346
Non-controlling interests		17,089	155,553	(38,970)	5,234
Profit/ (loss) after tax		(783,009)	(474,881)	(136,976)	16,580
Earnings per share					
Basic and diluted earnings per share (EPS) (in Taka)	18	(9.11)	(7.18)	(1.12)	0.13


Managing Director


Director


Chief Financial Officer


Company Secretary

Advanced Chemical Industries PLC
Consolidated statement of profit or loss and other comprehensive income
Unaudited

	Figures in '000' Taka			
	For the nine month ended from		For the 3rd quarter ended from	
	July 2024 to March 2025	July 2023 to March 2024	January 2025 to March 2025	January 2024 to March 2024
Profit/ (loss) after tax	(783,009)	(474,881)	(136,976)	16,580
Other comprehensive income:				
Foreign operations - foreign currency translation differences	(122,745)	(49,701)	(7,424)	133,962
Change in fair value of FVOCI financial assets	(6,789)	(49,133)	(6,257)	(43,152)
Income tax on other comprehensive income	1,018	4,913	939	4,315
Other comprehensive income, net of tax	(128,515)	(93,921)	(12,742)	95,125
Total comprehensive income	(911,524)	(568,802)	(149,718)	111,705
Total comprehensive income attributable to:				
Owners of the Company				
Profit/ (loss) after tax	(800,098)	(630,434)	(98,005)	11,346
Other comprehensive income	(117,361)	(79,525)	(9,614)	94,225
	(917,459)	(709,959)	(107,619)	105,571
Non-controlling interests				
Profit/ (loss) after tax	17,089	155,553	(38,970)	5,234
Other comprehensive income	(11,154)	(14,396)	(3,128)	900
	5,935	141,158	(42,099)	6,134
Total comprehensive income	(911,524)	(568,802)	(149,718)	111,705

Advanced Chemical Industries PLC
Consolidated statement of changes in equity
Unaudited

										Figures in '000' Taka	
										For the nine month ended from July 2024 to March 2025	
	Attributable to owners of the Company									Non-controlling Interests	Total equity
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Accumulated loss	Total		
Balance at 1 July 2024	762,056	1,254,116	56,854	1,671	(57,081)	272,821	5,852,066	(1,176,671)	6,965,832	1,591,894	8,557,727
Total comprehensive income											
Profit/ (loss) after tax	-	-	-	-	-	-	-	(800,098)	(800,098)	17,089	(783,009)
Other comprehensive income, net of tax	-	-	-	-	(110,699)	(6,662)	-	-	(117,361)	(11,154)	(128,515)
Total comprehensive income	-	-	-	-	(110,699)	(6,662)	-	(800,098)	(917,459)	5,935	(911,524)
Transaction with owners of the Company											
Issuance of merger consideration share	1,954	54,900	(56,854)	-	-	-	-	-	-	-	-
Stock dividend	114,602	-	-	-	-	-	-	(114,602)	-	-	-
Cash dividend	-	-	-	-	-	-	-	(152,802)	(152,802)	(226,933)	(379,735)
Capital contribution by non-controlling interests										2,300	2,300
Total transactions with owners of the Company	116,555	54,900	(56,854)	-	-	-	-	(267,404)	(152,802)	(224,633)	(377,435)
Balance at 31 March 2025	878,612	1,309,016	-	1,671	(167,781)	266,159	5,852,066	(2,244,172)	5,895,571	1,373,196	7,268,768
										For the nine months ended from July 2023 to March 2024	
	Attributable to owners of the Company									Non-controlling Interests	Total equity
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total		
Balance at 1 July 2023	762,056	1,254,116	-	1,671	(120,987)	389,978	5,860,112	515,470	8,662,417	1,884,856	10,547,273
Total comprehensive income											
Profit/ (loss) after tax	-	-	-	-	-	-	-	(630,434)	(630,434)	155,553	(474,881)
Other comprehensive income, net of tax	-	-	-	-	(43,887)	(35,639)	-	-	(79,525)	(14,396)	(93,921)
Total comprehensive income	-	-	-	-	(43,887)	(35,639)	-	(630,434)	(709,959)	141,158	(568,802)
Transaction with owners of the Company											
Stock dividend	-	-	-	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-	(304,823)	(304,823)	(347,706)	(652,529)
Total transactions with owners of the Company	-	-	-	-	-	-	-	(304,823)	(304,823)	(347,706)	(652,529)
Balance at 31 March 2024	762,056	1,254,116	-	1,671	(164,874)	354,339	5,860,112	(419,786)	7,647,635	1,678,308	9,325,943

Advanced Chemical Industries PLC
Consolidated statement of cash flows
Unaudited

		Figures in '000' Taka	
		For the nine month ended from	
		July 2024 to March 2025	July 2023 to March 2024
Cash flows from operating activities			
Cash receipts from customers and others		96,533,876	90,364,962
Cash paid to suppliers and employees		(95,306,008)	(88,760,161)
Cash generated from / (used in) operating activities		1,227,868	1,604,800
Paid to WPPF		(238,435)	(358,569)
Finance costs paid		(6,151,790)	(3,802,672)
Income tax paid		(2,139,738)	(1,926,784)
		(8,529,963)	(6,088,026)
Net cash from / (used in) operating activities *	16 (a)	(7,302,095)	(4,483,225)
Cash flows from investing activities			
Acquisition of property, plant and equipment		(487,785)	(666,149)
Payments for capital work-in-progress		(1,715,949)	(2,418,273)
Sale proceeds from property, plant and equipment		15,207	3,027
Purchase of biological assets		(6,314)	(14,894)
Dividend received		961,828	440,000
Short term investments		(7,759)	2,590,186
Long term investments		(452,942)	(281,734)
Net cash from / (used in) investing activities		(1,693,713)	(347,837)
Cash flows from financing activities			
Dividend paid		(151,099)	(303,629)
Dividend paid to non-controlling interests		(150,981)	(216,715)
Payment for lease liabilities		(437,398)	(371,954)
Short-term borrowing received/(paid)		10,207,783	3,036,738
Long-term borrowing received/(paid)		(1,054,148)	1,767,660
Net cash from / (used in) financing activities		8,414,157	3,912,100
Net increase / (decrease) in cash and cash equivalents		(581,652)	(918,963)
Opening cash and cash equivalents		(3,107,509)	(3,154,964)
Effect of movements in exchange rates on cash held		693	6,160
Closing cash and cash equivalents		(3,688,468)	(4,067,767)
Closing balance represents			
Cash and cash equivalents		6,566,609	3,785,456
Bank overdraft		(10,255,077)	(7,853,223)
		(3,688,468)	(4,067,767)
Net operating cash flow per share (NOCFPS) (in Taka)	18	(83.11)	(51.03)

*See Note 16(a) for reconciliation of consolidated net operating cash flow.

Advanced Chemical Industries PLC
Notes to the financial statements
As at and for the 3rd quarter ended on 31 March 2025
Unaudited

1 Selected explanatory notes

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended from 1 July 2023 to 30 June 2024. This interim financial report includes only those selected explanatory notes as deemed appropriate for better understanding of unaudited financial statements.

2	Property, plant and equipment	31 March 2025	Figures in '000' Taka 30 June 2024
		Taka	Taka
	Opening balance	23,093,157	18,382,467
	Additions during the period	1,431,232	1,755,503
	Disposals and adjustments	(59,886)	(39,809)
	Adjustment for Merger	-	2,994,996
	Accumulated depreciation	(5,620,908)	(5,141,702)
	Closing balance	18,843,595	17,951,455
2 (a)	Consolidated property, plant and equipment		
	Opening balance	45,716,051	41,925,146
	Additions during the period	2,340,550	3,837,166
	Disposals and adjustments	(87,877)	(46,261)
	Accumulated depreciation	(13,141,532)	(11,904,065)
	Closing balance	34,827,192	33,811,986
3	Investments		
	Investment in subsidiaries	1,877,438	1,877,638
	Investment in joint ventures	185,000	185,000
	Investment in associates	1,505,528	1,206,098
	Investment in shares	420,222	428,967
	Investment in FDR/ other deposits	256,864	208,335
	Impairment	(273,600)	(273,600)
		3,971,452	3,632,438
4	Inventories		
	Raw materials	4,090,031	3,907,948
	Packing materials	797,581	743,560
	Work-in-process	747,027	635,163
	Finished goods	3,313,996	3,293,828
	Goods in transit	878,610	608,197
	Stores and spares	227,146	221,170
	Allowance for inventory	(555,319)	(699,474)
		9,499,072	8,710,393

		31 March 2025	Figures in '000' Taka 30 June 2024
		Taka	Taka
4 (a)	Consolidated inventories		
	Raw materials	8,261,586	6,963,885
	Packing materials	925,241	885,774
	Work-in-process	1,062,311	924,843
	Finished goods	13,858,638	11,711,683
	Goods in transit	1,815,856	1,510,211
	Stores and spares	418,824	435,915
	Allowance for inventory	(1,183,932)	(1,142,160)
		25,158,524	21,290,152
5	Trade receivables		
	Debts due over six months	1,590,426	1,664,948
	Debts due below six months	4,150,504	3,181,230
	Provision for doubtful debts	(812,895)	(809,299)
		4,928,035	4,036,880
5 (a)	Consolidated trade receivables		
	Debts due over six months	4,723,355	4,664,177
	Debts due below six months	19,517,570	14,493,790
	Provision for doubtful debts	(1,595,537)	(1,518,138)
		22,645,388	17,639,830
6	Inter-company receivables		
	ACI Logistics Limited	15,802,854	13,385,397
	ACI HealthCare Limited	15,079,243	12,426,471
	ACI Foods Limited	2,523,360	2,431,888
	ACI Biotech Limited	2,001,115	1,606,226
	ACI Agrolink Limited	1,036,662	930,357
	ACI HealthCare USA Inc.	1,145,350	1,044,946
	Infolytx Bangladesh Limited	1,010,511	911,264
	ACI Chemicals Limited	298,785	274,529
	ACI Herbal and Nutraceuticals Limited	1,730	-
	ACI Premio Plastics Limited	1,245,268	1,115,467
	ACI Godrej Agrovat (Pvt.) Limited	948	935
	Computer Technology Limited	30	30
		40,145,856	34,127,510
7	Advances, deposits and prepayments		
	Advances to staff, suppliers and others	549,099	450,028
	VAT current account	41,815	93,191
	LC Margin	513,304	1,013,054
	Deposits	296,020	298,538
	Prepayments	189,690	63,489
		1,589,928	1,918,300

		31 March 2025	Figures in '000' Taka 30 June 2024
		Taka	Taka
7 (a)	Consolidated advances, deposits and prepayments		
	Advances to staff, suppliers and others	1,133,751	1,236,460
	VAT current account	147,116	119,093
	LC Margin	2,003,369	2,211,995
	Deposits	970,491	825,513
	Prepayments	358,866	219,002
	Advance for capital expenditure	21,740	19,532
		4,635,333	4,631,596
8	Employee benefits		
	Staff gratuity provision	1,445,442	1,251,874
	Other long term employee benefits	351,512	306,578
		1,796,954	1,558,453
8 (a)	Consolidated employee benefits		
	Staff gratuity provision	1,817,688	1,567,375
	Other long term employee benefits	492,640	419,452
		2,310,329	1,986,827
9	Long term borrowings		
	Long term bank loans	1,578,388	1,692,941
		1,578,388	1,692,941
9 (a)	Consolidated long term borrowings		
	Long term bank loans	5,912,157	6,943,562
		5,912,157	6,943,562
10	Loans and borrowings - short term		
	Short term loans	28,418,879	26,646,291
	Current portion of long term loans	639,171	588,951
		29,058,050	27,235,242
10 (a)	Consolidated loans and borrowings - short term		
	Short term loans	54,252,101	43,934,229
	Current portion of long term loans	4,071,330	4,086,107
		58,323,431	48,020,336
11	Inter company payables		
	ACI Marine and Riverine Technologies Limited	34,085	39,515
	ACI Motors Limited	491,911	499,653
	ACI Salt Limited	1,815,926	2,022,518
	ACI Pure Flour Limited	2,087,763	1,836,071
	ACI Edible Oils Limited	200,507	273,399
	Creative Communication Limited	14,032	33,155
	ACI Formulations PLC	2,251,005	1,554,359
	Stochastic Logic Limited	4,687	2,765
	ACI Avionics and Airlines Services Limited	9,165	-
		6,909,082	6,261,434

		31 March 2025	Figures in '000' Taka
		Taka	30 June 2024
			Taka
12	Other payables		
	Accruals	3,307,473	2,138,066
	Advance from customers	80,966	78,393
	Security money received from customers	23,262	36,907
	Workers' profit participation fund	935,163	985,324
	Tax and VAT deducted at source	193,086	130,101
	Employees welfare fund	375,078	362,715
	Rights share deposit to be refunded	564	564
	Family day fund	8,515	7,491
	Non-management staff provident fund	79,310	65,148
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
	Payable for redemption of Zero Coupon Bonds	20,403	20,403
	Management staff provident fund	11,926	44,124
	Advertisement and promotional funds	110,403	92,035
	Development funds	11,996	12,358
	Other finances	95,390	66,000
		5,257,185	4,043,278
12 (a)	Consolidated other payables		
	Accruals	6,837,562	5,360,006
	Advance from customers	370,217	1,252,781
	Security money received from customers	143,919	155,209
	Workers' profit participation fund	1,420,641	1,320,986
	Management staff provident fund	11,926	44,124
	Tax and VAT deducted at source	412,389	583,098
	Employees welfare fund	375,078	362,715
	Rights share deposit to be refunded	564	564
	Family day fund	8,515	7,491
	Non-management staff provident fund	79,310	65,148
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
	Payable for redemption of Zero Coupon Bonds	20,403	20,403
	Creditors for capital expenditure	18,028	18,343
	Advertisement and promotional funds	110,403	92,035
	Development funds	12,086	12,358
	Other finances	95,390	66,000
		9,920,080	9,364,909

Figures in '000' Taka	
For the nine month ended from	
July 2024 to March 2025 Taka	July 2023 to March 2024 Taka

13	Revenue		
	Pharmaceuticals	13,656,253	12,421,009
	Animal health	4,349,567	3,707,502
	Consumer brands	7,707,134	6,684,819
	Seed	1,611,768	1,430,319
	Fertilizer	1,753,744	1,333,695
	Flexible packaging	4,964,811	-
	Animal genetics and others	383,998	397,723
		34,427,276	25,975,066
13 (a)	Consolidated revenue		
	Gross sales	104,572,594	95,186,363
	Inter-company sales	(2,640,088)	(2,223,689)
		101,932,506	92,962,674
14	Cost of sales		
	Opening stock	8,580,500	6,876,275
	Purchase	18,975,150	14,274,047
		27,555,650	21,150,322
	Closing stock	(8,948,634)	(8,056,338)
		18,607,016	13,093,984
	Manufacturing expenses	2,910,441	2,119,367
		21,517,457	15,213,350
14 (a)	Consolidated cost of sales		
	Opening stock	20,478,216	21,408,984
	Purchase	74,331,872	67,804,203
		94,810,087	89,213,187
	Closing stock	(24,109,627)	(23,779,605)
		70,700,460	65,433,582
	Manufacturing expenses	5,873,699	5,314,663
		76,574,159	70,748,245
15	Administrative, selling and distribution expenses		
	Administrative expenses	621,830	476,140
	Distribution expenses	1,139,484	1,017,986
	Selling expenses	7,068,907	6,977,299
		8,830,221	8,471,425

Figures in '000' Taka	
For the nine month ended from	
July 2024 to March 2025 Taka	July 2023 to March 2024 Taka

15 (a) Consolidated administrative, selling and distribution expenses

Administrative expenses	2,101,593	2,365,524
Distribution expenses	2,169,626	1,994,219
Selling expenses	13,460,098	12,546,031
	17,731,317	16,905,774

16 Reconciliation of net operating cash flow

Profit after tax	3,273,566	2,299,897
<i>Adjustment for non-cash items and others:</i>		
-Unrealized gain on translation of foreign currency receivables	(34,960)	(22,991)
- Depreciation and amortisation	538,989	384,261
- Provisions	(130,842)	10,887
- Finance cost	905,890	158,513
- Tax expense	1,011,181	631,929
- Contribution to WPPF	225,513	154,307
-Lease and other adjustments	138,348	137,138
<i>Changes in:</i>		
- Inventories	(644,523)	(1,240,041)
- Trade and other receivables	(2,077,229)	(880,409)
- Advances, deposits and prepayments	(1,484)	(834,402)
- Trade and other payables, and employment benefits	1,086,005	1,864,322
Cash generated from operating activities	4,289,848	2,663,412
Paid to WPPF	(209,270)	(149,541)
Interest paid	(414,341)	(102,308)
Income tax paid	(1,090,583)	(661,735)
Net cash from operating activities	2,575,654	1,749,828

16 (a) Reconciliation of consolidated net operating cash flow

Profit/ (loss) after tax	(783,009)	(474,881)
<i>Adjustment for non-cash items and others:</i>		
- Depreciation and amortisation	1,376,876	1,307,491
- Provisions	119,171	81,050
- Share of profit of equity accounted investees	(364,099)	(497,020)
- Finance cost	6,685,097	4,723,848
- Tax expense	2,051,560	1,668,652
- Contribution to WPPF	358,900	278,084
-Lease and other adjustments	492,512	371,955

Changes in:

- Inventories	(3,910,143)	(2,642,483)
- Trade and other receivables	(5,388,758)	(2,708,657)
- Advances, deposits and prepayments	(329,845)	(2,527,838)
- Trade and other payables, and employment benefits	919,607	2,024,598
Net cash from operating activities	1,227,868	1,604,800

Paid to WPPF	(238,435)	(358,569)
Interest paid	(6,151,790)	(3,802,672)
Income tax paid	(2,139,738)	(1,926,784)
Net cash from operating activities	(7,302,095)	(4,483,225)

- 17 Consolidated operating segments
Please see Annexure A.

Figures in '000' Taka	
For the nine month ended from	
July 2024	July 2023
to	to
March 2025	March 2024

- 18 Consolidated EPS, NAV per share, and NOCFPS

Ordinary shares (Number)	87,861	87,861
Weighted average number of ordinary shares (in thousand)	87,861	87,861

Consolidated profit/ (loss) attributable to owners of the Company	(800,098)	(630,434)
Earnings per share (Taka)	(9.11)	(7.18)

Consolidated cash flows from operating activities (Taka '000)	(7,302,095)	(4,483,225)
Net operating cash flows per share (NOCFPS)	(83.11)	(51.03)

	31 March 2025	30 June 2024
	Taka	Taka
Consolidated net asset attributable to owners of the Company (Taka '000)	5,895,571	6,965,832
Net asset value (NAV) per share	67.10	79.28

Reasons for significant deviations: During the nine month ended on 31 March 2025, the Group achieved a 9.6% revenue growth which was contributed by a number of businesses as demonstrated in Consolidated Operating Segments in Annexure A. During the period, growth in gross profit exceeded the growth in operating expenses due to cost control initiatives which contributed to the improvement of the operating profit. On the other hand, cost of borrowing increased due to the increase of interest rate along with the additional funding for working capital and strategic investments for supporting business growth. Overall, the consolidated EPS was Taka (9.11) during the period against Taka (7.18) of SPLY. NOCFPS during the period was Taka (83.11) against Taka (51.03) as a result of the movement in the working capital level.

- 19 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

Annexure-A

Consolidated operating segments

Figures in '000' Taka
For the nine month ended from July 2024 to March 2025

Particulars	Reportable Segment												Total reportable segments	Unallocated/ Elimination	Total
	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Flexible Packaging	Consumer Plastics	HealthCare			
External revenue	13,656,253	4,349,567	7,423,787	3,220,412	26,074,366	4,943,921	19,781,990	2,309,532	7,193,755	4,707,313	2,259,681	571,210	96,491,787	5,440,719	101,932,506
Inter-segment revenue	-	-	819,478	-	68,465	339,982	60,151	92,604	396,136	257,498	-	415,922	2,450,238	189,850	2,640,088
Segment revenue	13,656,253	4,349,567	8,243,265	3,220,412	26,142,831	5,283,903	19,842,141	2,402,137	7,589,891	4,964,811	2,259,681	987,132	98,942,025	5,630,569	104,572,594
Depreciation and amortisation	258,663	22,806	64,931	18,449	103,823	25,733	131,748	73,751	69,362	131,063	72,894	300,577	1,273,800	103,076	1,376,876
Operating expenses	5,819,145	840,586	1,483,166	515,952	3,100,804	220,659	3,512,838	239,744	650,780	145,479	328,695	57,060	16,914,908	816,408	17,731,317
Finance cost / (income)	395,250	205,180	116,548	158,221	760,489	(51,725)	2,163,285	(110,464)	451,453	493,749	221,799	1,905,185	6,708,969	(23,872)	6,685,097
Segment profit/(loss) before tax	1,602,718	262,460	245,345	607,686	1,576,870	162,539	(1,962,022)	279,799	(176,304)	135,729	(124,240)	(2,193,722)	416,858	851,693	1,268,551
Segment assets at 31 March 2025	16,265,571	2,628,336	5,217,383	3,021,681	29,734,208	4,580,465	8,178,812	4,167,120	3,516,040	6,866,429	1,535,021	7,756,648	93,467,715	11,417,007	104,884,722
Segment liabilities at 31 March 2025	5,309,967	1,122,023	3,926,796	1,395,922	18,540,478	3,185,267	28,464,133	1,535,991	5,689,641	6,291,379	2,094,047	22,019,214	99,574,860	(1,958,905)	97,615,954

For the nine months ended from July 2023 to March 2024

Particulars	Reportable segment												Total reportable segments	Unallocated/ Elimination	Total
	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Flexible Packaging	Consumer Plastics	HealthCare			
External revenue	12,421,009	3,707,502	6,491,875	3,190,058	22,373,260	5,905,769	16,579,057	2,387,708	7,494,241	3,809,472	1,775,308	2,064,103	88,199,362	4,763,312	92,962,674
Inter-segment revenue	-	-	763,297	-	115,724	135,296	64,465	32,111	225,277	426,966	-	344,507	2,107,643	116,046	2,223,689
Segment revenue	12,421,009	3,707,502	7,255,173	3,190,058	22,488,984	6,041,064	16,643,522	2,419,819	7,719,519	4,236,438	1,775,308	2,408,610	90,307,005	4,879,358	95,186,363
Depreciation and amortisation	247,771	20,665	61,750	16,245	94,081	26,865	126,414	67,958	61,331	88,115	117,627	290,821	1,219,645	87,846	1,307,491
Operating expenses	5,845,604	754,922	1,485,870	511,791	2,626,699	223,652	2,990,491	262,813	546,687	122,719	335,804	515,951	16,223,003	682,770	16,905,774
Finance cost / (income)	340,250	159,620	134,074	117,016	676,109	(19,095)	1,498,220	(95,797)	369,632	302,314	225,038	1,299,133	5,006,513	(282,665)	4,723,848
Segment profit/(loss) before tax	958,695	109,099	119,712	455,786	1,750,735	107,927	(1,320,487)	92,499	(99,536)	183,941	(227,087)	(2,056,517)	74,768	1,119,004	1,193,772
Segment assets at 30 June 2024	15,853,828	2,278,089	3,888,578	2,782,408	23,443,792	3,072,145	7,412,010	4,435,938	3,195,653	6,172,399	1,366,994	8,067,161	81,968,995	12,125,736	94,094,731
Segment liabilities at 30 June 2024	4,660,309	1,226,754	2,140,012	1,116,551	12,898,438	1,785,926	25,615,972	2,004,606	5,151,499	5,589,299	1,781,442	19,946,458	83,917,266	1,619,739	85,537,004